Gene polymorphisms;Polymorphismes génétiques

Bulletin du Cancer

Volumn 97, Issue 11, 2010, Pages 1253-1264

  Robert, J ^a  

^a UNIVERSITÉ DE BORDEAUX   (France)

Author keywords

DNA structure; Genome; Molecular epidemiology; Mutations; Pharmacogenetics; Polymorphisms

Indexed keywords

ANTINEOPLASTIC AGENT;

ANTINEOPLASTIC ACTIVITY; CANCER EPIDEMIOLOGY; CANCER GENETICS; GENE MUTATION; GENE STRUCTURE; GENETIC POLYMORPHISM; HUMAN; MALIGNANT NEOPLASTIC DISEASE; MOLECULAR EPIDEMIOLOGY; ONCOGENE; PHARMACOGENETICS; REVIEW; SOMATIC MUTATION; TUMOR SUPPRESSOR GENE;

EID: 78650162575     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: 10.1684/bdc.2010.1203     Document Type: Review

References (32)

1. e édition, Paris : Masson, 2006, 294 p.
2. Brown TA. Génomes. Paris : Flammarion Médecine Sciences, 2004.
3. Syvanen AC. Accessing genetic variation: genotyping single nucleotide polymorphisms. Nat Rev Genet 2001 ; 2 : 930-42.
4. Kwok PY. Methods for genotyping single nucleotide polymorphisms. Annu Rev Genomics Hum Genet 2001 ; 2 : 235-58.
5. Shi MM. Enabling large-scale pharmacogenetic studies by high-throughput mutation detection and genotyping technologies. Clin Chem 2001 ; 47 : 164-72. (Pubitemid 32142913)
6. Shi MM, Bleavins MR, de la Iglesia FA. Technologies for detecting genetic polymorphisms in pharmacogenomics. Mol Diagn 1999 ; 4 : 343-51. (Pubitemid 30036374)
7. Till BJ, Burtner C, Comai L, Henikoff S. Mismatch cleavage by single-strand specific nucleases. Nucl Acid Res 2004 ; 32 : 2632-41. (Pubitemid 38854817)
8. Orita M, Suzuki Y, Sekiya T, Hayashi K. Rapid and sensitive detection of point mutations and DNA polymorphisms using the polymerase chain reaction. Genomics 1989 ; 5 : 874-9.
9. Behrensdorf HA, Pignot M, Windhab N, Kappel A. Rapid parallel mutation scanning of gene fragments using a microelectronic protein-DNA chip format. Nucl Acid Res 2002 ; 30 : e64.
10. Nelson HH, Kelsey KT, Mott LA, Karagas MR. The XRCC1 Arg399Gln polymorphism, sunburn, and non-melanoma skin cancer: evidence of gene-environment interaction. Cancer Res 2002 ; 62 : 152-5. (Pubitemid 34073999)
11. Setlur SR, Chen CX, Hossain RR, Ha JS, Van Doren VE, Steuzel B, et al. Genetic variation of genes involved in dihydrotestosterone metabolism and the risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 2010 ; 19 : 229-39.
12. Eeles RA, Kote-Jarai Z, Al Olama AA, Giles GG, Guy M, Severi G, et al. Identification of seven new prostate cancer susceptibility loci through a genome-wide association study. Nat Genet 2009 ; 41 : 1116-21.
13. Le Morvan V, Bellott R, Moisan F, Mathoulin-Pélissier S, Bonnet J, Robert J. Relationships between genetic polymorphisms and anticancer drug cytotoxicity «vis-à-vis» the NCI-60 panel. Pharmacogenomics 2006 ; 7 : 843-52.
14. Faur N, Araud L, Laroche-Clary A, Kanno J, Toutain J, Yamori T, et al. The association between the T309G polymorphism of the MDM2 gene and sensitivity to anticancer drug is dependent on the p53 mutational status in cellular models. Br J Cancer 2009 ; 101 : 350-6.
15. Huang RS, Duan S, Bleibel WK, Kistner EO, Zhang W, Clark TA, et al. A genome-wide approach to identify genetic variants that contribute to etoposide-induced cytotoxicity. Proc Natl Acad Sci USA 2007 ; 104 : 9758-63. (Pubitemid 47175340)
16. Robert J, Le Morvan V, Smith D, Pourquier P, Bonnet J. Predicting drug response and toxicity based on gene polymorphisms. Crit Rev Oncol Hematol 2005 ; 54 : 171-96. (Pubitemid 40693684)
17. McLeod HL, Evans WE. Pharmacogenomics: unlocking the human genome for better drug therapy. Annu Rev Pharmacol Toxicol 2001 ; 41 : 101-21. (Pubitemid 32385884)
18. Boddy AV, Ratain MJ. Pharmacogenetics in cancer etiology and chemotherapy. Clin Cancer Res 1997 ; 3 : 1025-30.
19. Loni L, Del Tacca M, Danesi R. Pharmacogenetics of anticancer drugs in non-Hodgkin lymphomas. Br J Cancer 2001 ; 85 : 1425-31. (Pubitemid 34001568)
20. Ensom MH, Chang TK, Patel P. Pharmacogenetics: the therapeutic drug monitoring of the future? Clin Pharmacokinet 2001 ; 40 : 783-802.
21. Sekine I, Saijo N. Polymorphisms of metabolizing enzymes and transporter proteins involved in the clearance of anticancer agents. Ann Oncol 2001 ; 12 : 1515-25. (Pubitemid 34065879)
22. Van Kuilenburg AB, Meinsma R, Zoetekouw L, Van Gennip AH. High prevalence of the IVS14 + 1G>A mutation in the dihydropyrimidine dehydrogenase gene of patients with severe 5-fluoro-uracil-associated toxicity. Pharmacogenetics 2002 ; 12 : 555-8. (Pubitemid 35177085)
23. Iyer L, Das S, Janisch L, Wen M, Ramirez J, Karrison T, et al. UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity. Pharmacogenomics J 2002 ; 2 : 43-7. (Pubitemid 34982202)
24. Dumont P, Leu JI, Della Pietra 3rd AC, George DL, Murphy M. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet 2003 ; 33 : 357-65. (Pubitemid 36278852)
25. Sullivan A, Syed N, Gasco M, Bergamaschi D, Trigiante G, Attard M, et al. Polymorphism in wild-type p53 modulates response to chemotherapy in vitro and in vivo. Oncogene 2004 ; 23 : 3328-37. (Pubitemid 38669822)
26. Bergamaschi D, Gasco M, Hiller L, Sullivan A, Syed N, Trigiante G, et al. p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis. Cancer Cell 2003 ; 3 : 387-402. (Pubitemid 38340307)
27. Wegman P, Stal O, Askmalm MS, Nordenskjold B, Rutqvist LE, Wingren S. p53 polymorphic variants at codon 72 and the outcome of therapy in randomized breast cancer patients. Pharmacogenet Genomics 2006 ; 16 : 347-51.
28. Bond GL, Hu W, Bond EE, Robins H, Lutzker SG, Arva NC, et al. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 2004 ; 119 : 591-602. (Pubitemid 39535748)
29. Stearns V, Johnson MD, Rae JM, Morocho A, Novielli A, Bhargava P, et al. Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst 2003 ; 95 : 1758-64. (Pubitemid 38008898)
30. Goetz MP, Rae JM, Suman VJ, Safgren SL, Ames MM, Visscher DW, et al. Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol 2005 ; 23 : 9312-8.
31. Borges S, Desta Z, Li L, Skaar TC, Ward BA, Nguyen A, et al. Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment. Clin Pharmacol Ther 2006 ; 80 : 61-74. (Pubitemid 43946844)
32. Schroth W, Antoniadou L, Fritz P, Schwab M, Muerdter T, Zanger UM, et al. Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes. J Clin Oncol 2007 ; 25 : 5187-93. (Pubitemid 350232249)